Vitale, Martina
Orsi, Emanuela
Solini, Anna
Garofolo, Monia
Grancini, Valeria
Bonora, Enzo
Fondelli, Cecilia
Trevisan, Roberto
Vedovato, Monica
Penno, Giuseppe
Nicolucci, Antonio
Pugliese, Giuseppe http://orcid.org/0000-0003-1574-0397
,
Funding for this research was provided by:
Fondazione Diabete Ricerca
Fondazione Diabete Endocrinologia Metabolismo
Eli Lilly and Company
Sigma-Tau Pharmaceuticals
Boehringer Ingelheim
Chiesi Farmaceutici
Takeda Pharmaceutical Company
Università degli Studi di Roma La Sapienza
Article History
Received: 29 February 2024
Accepted: 14 April 2024
First Online: 7 May 2024
Declarations
:
: MVi: lecture fees from MundiPharma and Novo Nordisk. EO: consultant fees from Eli Lilly and Novo Nordisk, and lecture fees from Astellas. AS: consultant fees from Axxam, Bayer, and Novo Nordisk, and lecture fees from Eli Lilly, Novo Nordisk, and Sanofi-Aventis. MG: consultant fees from Eli Lilly, and lecture fees from Eli Lilly, Merck Sharp & Dohme, and Novo Nordisk. VG: lecture fees from Abbot, Astra-Zeneca, Medtronic, Novo Nordisk, Sanofi-Aventis, Theras, and Vertex. EB: consultant fees from Abbott, Bayer, Becton Dickinson, Boehringer Ingelheim, Daiichi-Sankyo, Eli Lilly, and Novo Nordisk. CF: lecture fees from Abbot, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly, Merck Sharp & Dohme, Mundipharma, and Theras Lifetech. RT: consultant fees from AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Merck Sharp & Dohme, Novo Nordisk, and Sanofi-Aventis, and lecture fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly, and Novo Nordisk. MVe: lecture fees from Lifescan and Novo Nordisk. AN grant from Artsana, Astra-Zeneca, Eli Lilly, Novo Nordisk, and Sanofi Aventis and personal fees from Eli Lilly and Novo Nordisk. GPe: consultant fees from Bayer and Eli Lilly, and lecture fees from AstraZeneca, Boerhinger Ingelheim, Eli-Lilly, Merck Sharp & Dohme, Mundipharma, Novo Nordisk, and Takeda. GPu: consultant fees from Abbot, Bayer, and Novo Nordisk, and lecture fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Mundipharma, and Novo Nordisk.
: The study was conducted in accordance with the Declaration of Helsinki. The research protocol was approved by the ethics committee of the coordinating center (Sant’Andrea University Hospital, Rome, Italy) on 25 September 2006 (number 43/2006) and subsequently by the ethics committee of each participating center.
: Participants provided an informed consent.
: Not applicable.